Synergies between Small RNA and Protein Biomarkers for Early Detection of Cognitive Impairment – results from EPAD

Abstract

Background: Alzheimer's disease (AD), the most common form of dementia, is typically diagnosed using the AT(N) framework, which assesses amyloid, tau, and neurodegeneration biomarkers. However, this framework has limitations, particularly in predicting cognitive decline among amyloid‐positive individuals.